Cross-Sector entity
The 160-day window averages about 0.2 stories each week. The busiest single day carried 2. HMI-115 is the most frequent co-covered peer, appearing in 2 of the 5 tracked stories. The clearest coverage concentration is pharma: 2 of 5 stories, with the rest divided among 3 other categories.
5 verified stories tracked
Last mentioned: Jul 27, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 20 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
The 160-day window averages about 0.2 stories each week. The busiest single day carried 2. HMI-115 is the most frequent co-covered peer, appearing in 2 of the 5 tracked stories. The clearest coverage concentration is pharma: 2 of 5 stories, with the rest divided among 3 other categories. Each carries 2.4 original sources on average. Negative sentiment appears in 40% of the tracked stories. This profile follows 5 Cross-Sector stories mentioning Bayer across the period from February 18, 2026 to July 27, 2026.
Computed from the 5 stories linked to this entity. Beat comparisons are omitted because no baseline was available for this window.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Bayer. Shared-story counts are live from our verified record — not editorial picks.
End of Certainty Period
The 21-year structured resolution period is slated to conclude.
Phase III Initiation
First patient dosed in the pivotal Phase III clinical trial for endometriosis.
$7.25B Settlement Announced
Bayer agrees to a new $7.25 billion deal with a 21-year certainty plan.
Future Claims Deal
Bayer reaches a $7.25 billion agreement to resolve future litigation over a 21-year period.
Phase II Completion
Positive results from Phase II studies demonstrate pain reduction and safety.
Initial $10B Settlement
Bayer announces a massive settlement to resolve current claims, but future liability remains.
Licensing Agreement
Hope Medicine acquires global rights for HMI-115 from Bayer.
First Major Verdict
A California jury awards $289M to a groundskeeper, sparking a wave of litigation.
Monsanto Acquisition
Bayer completes $63 billion acquisition of Monsanto, inheriting Roundup litigation.
A new DelveInsight forecast projects a 47% CAGR for the Alport syndrome market through 2036, fueled by a pipeline of gene and targeted therapies. The report highlights ELX-02 from Eloxx as a potential first-mover gene therapy with an 8-week dosing interval, while big pharma players like Bayer and Novartis advance competitors.
Source: prnewswire.com · finanznachrichten.de
Hope Medicine has officially initiated its Phase III clinical trial for endometriosis, dosing the first patient with HMI-115. This milestone marks a significant advancement in the development of a first-in-class prolactin receptor antagonist designed to address the high unmet need in women's health.
Hope Medicine has officially initiated its global Phase III clinical trial for HMI-115, a first-in-class monoclonal antibody targeting the prolactin receptor for endometriosis. The dosing of the first patient marks a critical transition toward non-hormonal therapeutic options for a condition affecting nearly 10% of women globally.
Source: manilatimes.net · prnewswire.com
Bayer has reached a definitive $7.25 billion settlement to resolve future Roundup litigation, implementing a 21-year framework designed to provide financial and legal certainty. The deal aims to move the German conglomerate past the glyphosate-related liabilities that have weighed on its valuation since the 2018 Monsanto acquisition.
Bayer has reached a $7.25 billion settlement agreement to resolve long-standing litigation surrounding its Roundup herbicide. The deal includes a 21-year framework designed to provide legal and financial certainty for the company following years of costly courtroom battles.
